Anti-Human EG-VEGF
| Code | Size | Price |
|---|
| LEI-E146-25ug | 25 ug | £375.00 |
Quantity:
| LEI-E146-100ug | 100 ug | £659.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Caprine (Goat)
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Application: Western Blot (WB)
Shipping:
Ambient
Storage:
The lyophilized antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for twelve months from date of receipt. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.
Further Information
Antigen Distribution:
Human EG-VEGF is a secreted angiogenetic mitogen growth factor expressed in the steroidogenic glands, ovary, testis, adrenal and placenta.
Conjugate/Tag/Label:
Antigen Affinity Purified
Format:
This antigen affinity purified polyclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.2 ? 7.3 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.
Formulation:
This antigen affinity purified polyclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.2 ? 7.3 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.
Immunogen:
Purified Recombinant Human EG-VEGF (>98%)
Long Description:
Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF) or Prokineticin-1 (PK-1) is a novel secreted protein expressed in various tissues including steroidogenic glands. Although structurally non-related to VEGF, EG-VEGF/PK-1 was shown to promote angiogenesis acting via two G-protein coupled receptors (PK-R1 and PK-R2). 1 EG-VEGF is mitogen specific for the endothelium of steroidogenic glands. It induces proliferation, migration and fenestration in capillary endothelial cells derived from endocrine glands. EG-VEGF mRNA expression is localized to the steroid hormone-producing cells, i.e. Leydig cells of the testis and the specialized stroma in the ovary. 2 EG-VEGF increased the phosphorylation of Akt in a phosphatidylinositol 3-kinase-dependent manner and is a survival factor for ACE cells. EG-VEGF, possibly through binding to a G-protein coupled receptor, results in the activation of MAPK p44/42 and phosphatidylinositol 3-kinase signaling pathways, leading to proliferation, migration, and survival of responsive endothelial cells. 3
NCBI Gene:
84432
Target:
EG-VEGF
References
1. Meidan, R. et al. (2005) Endocrinology. 146(9):3950-8.
2. Ferrara, N. et al. (2002) Cold Spring Harb Symp Quant Biol.67:217-21.
3. Ferrara, N. et al. (2002) J Biol Chem. 277(10):8724-9.
Related Products
| Product Name | Product Code | Supplier | Anti-Human EG-VEGF-Biotin | LEI-E147 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-Human EG-VEGF (Clone 188608) | LEI-E190 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human EG-VEGF (Clone 188601) | LEI-E320 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Human EG-VEGF | LEI-V108 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||